References

References:

  • Alshaikh S, Lapadat R, Atieh MK, et al. The utilization and utility of immunostains in body fluid cytology. Cancer Cytopathol. 2020;128(6):384-391.
  • Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203(2):681-687.
  • Elahi M, Lam H, Adams C, Li QK. Cytologic diagnosis and differential diagnosis of histiocytic signet ring cells in effusion specimens. Cytojournal. 2024;21:30. Published 2024 Sep 2.
  • Hansford S, Kaurah P, Li-Chang H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015;1(1):23–32.
  • Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142(1):89-108.
  • Sundling KE, Cibas ES. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology. Cancer Cytopathol. 2018;126 Suppl 8:590-598.
  • van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361-374.
  • Yu GH, De Frias DV, Horcher AM. Evaluation of histochemical methods for the detection of intracytoplasmic mucin in serous effusions. Cytopathology. 1999;10(5):298-302.